Le SIDA en Afrique subsaharienne (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa

Identifieur interne : 000256 ( Istex/Corpus ); précédent : 000255; suivant : 000257

Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa

Auteurs : R G White ; E E Freeman ; K K Orroth ; R. Bakker ; H A Weiss ; N. O Arrell ; A. Buvé ; R J Hayes ; J R Glynn

Source :

RBID : ISTEX:0956EE2D6869A23BCC72701C677045799E4669CB

English descriptors

Abstract

Background: Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown. Methods: The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model STDSIM fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness. Results: Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (<5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%. Conclusions: These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.

Url:
DOI: 10.1136/sti.2008.029918

Links to Exploration step

ISTEX:0956EE2D6869A23BCC72701C677045799E4669CB

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
<author>
<name sortKey="White, R G" sort="White, R G" uniqKey="White R" first="R G" last="White">R G White</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Freeman, E E" sort="Freeman, E E" uniqKey="Freeman E" first="E E" last="Freeman">E E Freeman</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Orroth, K K" sort="Orroth, K K" uniqKey="Orroth K" first="K K" last="Orroth">K K Orroth</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Bakker, R" sort="Bakker, R" uniqKey="Bakker R" first="R" last="Bakker">R. Bakker</name>
<affiliation>
<mods:affiliation>Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Weiss, H A" sort="Weiss, H A" uniqKey="Weiss H" first="H A" last="Weiss">H A Weiss</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="O Arrell, N" sort="O Arrell, N" uniqKey="O Arrell N" first="N" last="O Arrell">N. O Arrell</name>
<affiliation>
<mods:affiliation>Pasteur Suite, Ealing Hospital, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Buve, A" sort="Buve, A" uniqKey="Buve A" first="A" last="Buvé">A. Buvé</name>
<affiliation>
<mods:affiliation>Institute of Tropical Medicine, Antwerp, Belgium</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hayes, R J" sort="Hayes, R J" uniqKey="Hayes R" first="R J" last="Hayes">R J Hayes</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Glynn, J R" sort="Glynn, J R" uniqKey="Glynn J" first="J R" last="Glynn">J R Glynn</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0956EE2D6869A23BCC72701C677045799E4669CB</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1136/sti.2008.029918</idno>
<idno type="url">https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000256</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000256</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
<author>
<name sortKey="White, R G" sort="White, R G" uniqKey="White R" first="R G" last="White">R G White</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Freeman, E E" sort="Freeman, E E" uniqKey="Freeman E" first="E E" last="Freeman">E E Freeman</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Orroth, K K" sort="Orroth, K K" uniqKey="Orroth K" first="K K" last="Orroth">K K Orroth</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Bakker, R" sort="Bakker, R" uniqKey="Bakker R" first="R" last="Bakker">R. Bakker</name>
<affiliation>
<mods:affiliation>Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Weiss, H A" sort="Weiss, H A" uniqKey="Weiss H" first="H A" last="Weiss">H A Weiss</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="O Arrell, N" sort="O Arrell, N" uniqKey="O Arrell N" first="N" last="O Arrell">N. O Arrell</name>
<affiliation>
<mods:affiliation>Pasteur Suite, Ealing Hospital, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Buve, A" sort="Buve, A" uniqKey="Buve A" first="A" last="Buvé">A. Buvé</name>
<affiliation>
<mods:affiliation>Institute of Tropical Medicine, Antwerp, Belgium</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hayes, R J" sort="Hayes, R J" uniqKey="Hayes R" first="R J" last="Hayes">R J Hayes</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Glynn, J R" sort="Glynn, J R" uniqKey="Glynn J" first="J R" last="Glynn">J R Glynn</name>
<affiliation>
<mods:affiliation>London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Sexually Transmitted Infections</title>
<title level="j" type="abbrev">Sex Transm Infect</title>
<idno type="ISSN">1368-4973</idno>
<idno type="eISSN">1472-3263</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd</publisher>
<date type="published" when="2008-10">2008-10</date>
<biblScope unit="volume">84</biblScope>
<biblScope unit="issue">Suppl 2</biblScope>
<biblScope unit="page" from="12">ii12</biblScope>
</imprint>
<idno type="ISSN">1368-4973</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1368-4973</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Acyclovir</term>
<term>African cities</term>
<term>Aids celum</term>
<term>Alternative scenarios</term>
<term>Antiviral therapy</term>
<term>Available data</term>
<term>Behaviour</term>
<term>Central african republic</term>
<term>Clin init</term>
<term>Cotonou</term>
<term>Effective vaccine</term>
<term>Episodic</term>
<term>Episodic therapy</term>
<term>Full details</term>
<term>General population</term>
<term>Genital</term>
<term>Herpes</term>
<term>Herpes simplex</term>
<term>Herpes simplex virus</term>
<term>Herpes simplex virus type</term>
<term>High coverage</term>
<term>High symptom recognition</term>
<term>High value</term>
<term>Higher proportion</term>
<term>Immunodeficiency</term>
<term>Important impact</term>
<term>Incidence</term>
<term>Kisumu</term>
<term>Korenromp</term>
<term>Largest effect</term>
<term>London school</term>
<term>Long duration</term>
<term>Long duration effects</term>
<term>Long duration therapy</term>
<term>Long term</term>
<term>Longitudinal studies</term>
<term>Male circumcision</term>
<term>Medium scenario options</term>
<term>Multicentre study</term>
<term>Natural history</term>
<term>Online</term>
<term>Online supplement</term>
<term>Orroth</term>
<term>Parameter sets</term>
<term>Percentage reduction</term>
<term>Plausible range</term>
<term>Population level</term>
<term>Potential impact</term>
<term>Prevalence</term>
<term>Prevalence trends</term>
<term>Recurrent ulcers</term>
<term>Scenario</term>
<term>Sensitivity analysis</term>
<term>Seropositive women</term>
<term>Sexual behaviour</term>
<term>Significant impact</term>
<term>Significant reduction</term>
<term>Simplex</term>
<term>Study group</term>
<term>Substantial impact</term>
<term>Supplement figure</term>
<term>Suppressive</term>
<term>Suppressive therapy</term>
<term>Suppressive therapy suppressive therapy</term>
<term>Symptom recognition</term>
<term>Symptomatic individuals</term>
<term>Target group</term>
<term>Therapy</term>
<term>Therapy type</term>
<term>Transm</term>
<term>Treatment duration</term>
<term>Treatment initiation</term>
<term>Tropical medicine</term>
<term>Ulcer</term>
<term>Ulcer duration</term>
<term>Viral load</term>
<term>Wellcome trust</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Acyclovir</term>
<term>African cities</term>
<term>Aids celum</term>
<term>Alternative scenarios</term>
<term>Antiviral therapy</term>
<term>Available data</term>
<term>Behaviour</term>
<term>Central african republic</term>
<term>Clin init</term>
<term>Cotonou</term>
<term>Effective vaccine</term>
<term>Episodic</term>
<term>Episodic therapy</term>
<term>Full details</term>
<term>General population</term>
<term>Genital</term>
<term>Herpes</term>
<term>Herpes simplex</term>
<term>Herpes simplex virus</term>
<term>Herpes simplex virus type</term>
<term>High coverage</term>
<term>High symptom recognition</term>
<term>High value</term>
<term>Higher proportion</term>
<term>Immunodeficiency</term>
<term>Important impact</term>
<term>Incidence</term>
<term>Kisumu</term>
<term>Korenromp</term>
<term>Largest effect</term>
<term>London school</term>
<term>Long duration</term>
<term>Long duration effects</term>
<term>Long duration therapy</term>
<term>Long term</term>
<term>Longitudinal studies</term>
<term>Male circumcision</term>
<term>Medium scenario options</term>
<term>Multicentre study</term>
<term>Natural history</term>
<term>Online</term>
<term>Online supplement</term>
<term>Orroth</term>
<term>Parameter sets</term>
<term>Percentage reduction</term>
<term>Plausible range</term>
<term>Population level</term>
<term>Potential impact</term>
<term>Prevalence</term>
<term>Prevalence trends</term>
<term>Recurrent ulcers</term>
<term>Scenario</term>
<term>Sensitivity analysis</term>
<term>Seropositive women</term>
<term>Sexual behaviour</term>
<term>Significant impact</term>
<term>Significant reduction</term>
<term>Simplex</term>
<term>Study group</term>
<term>Substantial impact</term>
<term>Supplement figure</term>
<term>Suppressive</term>
<term>Suppressive therapy</term>
<term>Suppressive therapy suppressive therapy</term>
<term>Symptom recognition</term>
<term>Symptomatic individuals</term>
<term>Target group</term>
<term>Therapy</term>
<term>Therapy type</term>
<term>Transm</term>
<term>Treatment duration</term>
<term>Treatment initiation</term>
<term>Tropical medicine</term>
<term>Ulcer</term>
<term>Ulcer duration</term>
<term>Viral load</term>
<term>Wellcome trust</term>
<term>World health organization</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Background: Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown. Methods: The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model STDSIM fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness. Results: Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (<5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%. Conclusions: These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.</div>
</front>
</TEI>
<istex>
<corpusName>bmj</corpusName>
<keywords>
<teeft>
<json:string>suppressive</json:string>
<json:string>herpes</json:string>
<json:string>suppressive therapy</json:string>
<json:string>episodic</json:string>
<json:string>genital</json:string>
<json:string>episodic therapy</json:string>
<json:string>simplex</json:string>
<json:string>transm</json:string>
<json:string>cotonou</json:string>
<json:string>high coverage</json:string>
<json:string>kisumu</json:string>
<json:string>herpes simplex virus type</json:string>
<json:string>online</json:string>
<json:string>general population</json:string>
<json:string>online supplement</json:string>
<json:string>orroth</json:string>
<json:string>full details</json:string>
<json:string>herpes simplex virus</json:string>
<json:string>scenario</json:string>
<json:string>acyclovir</json:string>
<json:string>korenromp</json:string>
<json:string>immunodeficiency</json:string>
<json:string>ulcer duration</json:string>
<json:string>symptom recognition</json:string>
<json:string>long term</json:string>
<json:string>long duration</json:string>
<json:string>sensitivity analysis</json:string>
<json:string>target group</json:string>
<json:string>potential impact</json:string>
<json:string>tropical medicine</json:string>
<json:string>natural history</json:string>
<json:string>therapy</json:string>
<json:string>prevalence</json:string>
<json:string>incidence</json:string>
<json:string>antiviral therapy</json:string>
<json:string>london school</json:string>
<json:string>sexual behaviour</json:string>
<json:string>recurrent ulcers</json:string>
<json:string>significant reduction</json:string>
<json:string>supplement figure</json:string>
<json:string>seropositive women</json:string>
<json:string>high symptom recognition</json:string>
<json:string>ulcer</json:string>
<json:string>behaviour</json:string>
<json:string>prevalence trends</json:string>
<json:string>long duration therapy</json:string>
<json:string>substantial impact</json:string>
<json:string>high value</json:string>
<json:string>plausible range</json:string>
<json:string>symptomatic individuals</json:string>
<json:string>longitudinal studies</json:string>
<json:string>higher proportion</json:string>
<json:string>significant impact</json:string>
<json:string>suppressive therapy suppressive therapy</json:string>
<json:string>percentage reduction</json:string>
<json:string>central african republic</json:string>
<json:string>world health organization</json:string>
<json:string>study group</json:string>
<json:string>medium scenario options</json:string>
<json:string>largest effect</json:string>
<json:string>therapy type</json:string>
<json:string>treatment duration</json:string>
<json:string>parameter sets</json:string>
<json:string>clin init</json:string>
<json:string>alternative scenarios</json:string>
<json:string>long duration effects</json:string>
<json:string>important impact</json:string>
<json:string>effective vaccine</json:string>
<json:string>african cities</json:string>
<json:string>wellcome trust</json:string>
<json:string>available data</json:string>
<json:string>herpes simplex</json:string>
<json:string>aids celum</json:string>
<json:string>viral load</json:string>
<json:string>population level</json:string>
<json:string>male circumcision</json:string>
<json:string>multicentre study</json:string>
<json:string>treatment initiation</json:string>
</teeft>
</keywords>
<author>
<json:item>
<name>R G White</name>
<affiliations>
<json:string>London School of Hygiene and Tropical Medicine, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>E E Freeman</name>
<affiliations>
<json:string>London School of Hygiene and Tropical Medicine, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>K K Orroth</name>
<affiliations>
<json:string>London School of Hygiene and Tropical Medicine, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>R Bakker</name>
<affiliations>
<json:string>Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>H A Weiss</name>
<affiliations>
<json:string>London School of Hygiene and Tropical Medicine, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>N O’Farrell</name>
<affiliations>
<json:string>Pasteur Suite, Ealing Hospital, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>A Buvé</name>
<affiliations>
<json:string>Institute of Tropical Medicine, Antwerp, Belgium</json:string>
</affiliations>
</json:item>
<json:item>
<name>R J Hayes</name>
<affiliations>
<json:string>London School of Hygiene and Tropical Medicine, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>J R Glynn</name>
<affiliations>
<json:string>London School of Hygiene and Tropical Medicine, London, UK</json:string>
</affiliations>
</json:item>
</author>
<articleId>
<json:string>st29918</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>research-article</json:string>
</originalGenre>
<abstract>Background: Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown. Methods: The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model STDSIM fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness. Results: Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (>5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%. Conclusions: These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.</abstract>
<qualityIndicators>
<score>7.751</score>
<pdfVersion>1.2</pdfVersion>
<pdfPageSize>595.276 x 793.701 pts</pdfPageSize>
<refBibsNative>false</refBibsNative>
<keywordCount>0</keywordCount>
<abstractCharCount>1856</abstractCharCount>
<pdfWordCount>4751</pdfWordCount>
<pdfCharCount>30236</pdfCharCount>
<pdfPageCount>7</pdfPageCount>
<abstractWordCount>269</abstractWordCount>
</qualityIndicators>
<title>Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
<pmid>
<json:string>18799486</json:string>
</pmid>
<genre>
<json:string>research-article</json:string>
</genre>
<host>
<title>Sexually Transmitted Infections</title>
<language>
<json:string>unknown</json:string>
</language>
<issn>
<json:string>1368-4973</json:string>
</issn>
<eissn>
<json:string>1472-3263</json:string>
</eissn>
<publisherId>
<json:string>sti</json:string>
</publisherId>
<volume>84</volume>
<issue>Suppl 2</issue>
<pages>
<first>ii12</first>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
</host>
<categories>
<wos>
<json:string>science</json:string>
<json:string>infectious diseases</json:string>
</wos>
<scienceMetrix>
<json:string>health sciences</json:string>
<json:string>public health & health services</json:string>
<json:string>public health</json:string>
</scienceMetrix>
<inist>
<json:string>sciences appliquees, technologies et medecines</json:string>
<json:string>sciences biologiques et medicales</json:string>
<json:string>sciences medicales</json:string>
<json:string>sante publique. hygiene-medecine du travail</json:string>
</inist>
</categories>
<publicationDate>2008</publicationDate>
<copyrightDate>2008</copyrightDate>
<doi>
<json:string>10.1136/sti.2008.029918</json:string>
</doi>
<id>0956EE2D6869A23BCC72701C677045799E4669CB</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main" xml:lang="en">Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd</publisher>
<availability status="free">
<p>Open Access</p>
</availability>
<date>2008-09-17</date>
</publicationStmt>
<notesStmt>
<note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc>
<biblStruct type="inbook">
<analytic>
<title level="a" type="main" xml:lang="en">Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
<author xml:id="author-0000">
<persName>
<forename type="first">R G</forename>
<surname>White</surname>
</persName>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
</author>
<author xml:id="author-0001">
<persName>
<forename type="first">E E</forename>
<surname>Freeman</surname>
</persName>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
</author>
<author xml:id="author-0002">
<persName>
<forename type="first">K K</forename>
<surname>Orroth</surname>
</persName>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
</author>
<author xml:id="author-0003">
<persName>
<forename type="first">R</forename>
<surname>Bakker</surname>
</persName>
<affiliation>Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</affiliation>
</author>
<author xml:id="author-0004">
<persName>
<forename type="first">H A</forename>
<surname>Weiss</surname>
</persName>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
</author>
<author xml:id="author-0005">
<persName>
<forename type="first">N</forename>
<surname>O’Farrell</surname>
</persName>
<affiliation>Pasteur Suite, Ealing Hospital, London, UK</affiliation>
</author>
<author xml:id="author-0006">
<persName>
<forename type="first">A</forename>
<surname>Buvé</surname>
</persName>
<affiliation>Institute of Tropical Medicine, Antwerp, Belgium</affiliation>
</author>
<author xml:id="author-0007">
<persName>
<forename type="first">R J</forename>
<surname>Hayes</surname>
</persName>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
</author>
<author xml:id="author-0008">
<persName>
<forename type="first">J R</forename>
<surname>Glynn</surname>
</persName>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
</author>
<idno type="istex">0956EE2D6869A23BCC72701C677045799E4669CB</idno>
<idno type="ark">ark:/67375/NVC-5LC8PKZ3-L</idno>
<idno type="DOI">10.1136/sti.2008.029918</idno>
<idno type="href">sextrans-84-ii12.pdf</idno>
<idno type="article-id">st29918</idno>
<idno type="PMID">18799486</idno>
<idno type="local">sextrans;84/Suppl_2/ii12</idno>
</analytic>
<monogr>
<title level="j">Sexually Transmitted Infections</title>
<title level="j" type="abbrev">Sex Transm Infect</title>
<idno type="pISSN">1368-4973</idno>
<idno type="eISSN">1472-3263</idno>
<idno type="publisher-id">sti</idno>
<idno type="PublisherID-hwp">sextrans</idno>
<idno type="PublisherID-nlm-ta">Sex Transm Infect</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd</publisher>
<date type="published" when="2008-10"></date>
<biblScope unit="volume">84</biblScope>
<biblScope unit="issue">Suppl 2</biblScope>
<biblScope unit="page" from="12">ii12</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<creation>
<date>2008-09-17</date>
</creation>
<langUsage>
<language ident="en">en</language>
</langUsage>
<abstract>
<p>Background: Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown. Methods: The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model STDSIM fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness. Results: Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (<5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%. Conclusions: These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.</p>
</abstract>
</profileDesc>
<revisionDesc>
<change when="2008-09-17">Created</change>
<change when="2008-10">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType>
<istex:document>
<article article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">sextrans</journal-id>
<journal-id journal-id-type="nlm-ta">Sex Transm Infect</journal-id>
<journal-id journal-id-type="publisher-id">sti</journal-id>
<journal-title>Sexually Transmitted Infections</journal-title>
<abbrev-journal-title abbrev-type="publisher">Sex Transm Infect</abbrev-journal-title>
<issn pub-type="ppub">1368-4973</issn>
<issn pub-type="epub">1472-3263</issn>
<publisher>
<publisher-name>BMJ Publishing Group Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">st29918</article-id>
<article-id pub-id-type="doi">10.1136/sti.2008.029918</article-id>
<article-id pub-id-type="other">sextrans;84/Suppl_2/ii12</article-id>
<article-id pub-id-type="pmid">18799486</article-id>
<article-id pub-id-type="other">ii12</article-id>
<article-id pub-id-type="other">sti.2008.029918</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Supplement</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</article-title>
<alt-title alt-title-type="running-head">Supplement</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>White</surname>
<given-names>R G</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Freeman</surname>
<given-names>E E</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Orroth</surname>
<given-names>K K</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Bakker</surname>
<given-names>R</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Weiss</surname>
<given-names>H A</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>O’Farrell</surname>
<given-names>N</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Buvé</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hayes</surname>
<given-names>R J</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Glynn</surname>
<given-names>J R</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<addr-line>London School of Hygiene and Tropical Medicine, London, UK</addr-line>
</aff>
<aff id="aff2">
<label>2</label>
<addr-line>Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</addr-line>
</aff>
<aff id="aff3">
<label>3</label>
<addr-line>Pasteur Suite, Ealing Hospital, London, UK</addr-line>
</aff>
<aff id="aff4">
<label>4</label>
<addr-line>Institute of Tropical Medicine, Antwerp, Belgium</addr-line>
</aff>
<author-notes>
<corresp>Dr R G White, Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK;
<email xlink:type="simple">richard.white@lshtm.ac.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2008</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>9</month>
<year>2008</year>
</pub-date>
<volume>84</volume>
<volume-id pub-id-type="other">84</volume-id>
<volume-id pub-id-type="other">84</volume-id>
<issue>Suppl 2</issue>
<issue-id pub-id-type="other">sextrans;84/Suppl_2</issue-id>
<issue-id pub-id-type="other" content-type="supplement">Suppl_2</issue-id>
<issue-id pub-id-type="other">84/Suppl_2</issue-id>
<issue-title>From efficacy to effectiveness; from effectiveness to impact</issue-title>
<fpage>ii12</fpage>
<history>
<date date-type="accepted">
<day>30</day>
<month>4</month>
<year>2008</year>
</date>
</history>
<permissions>
<copyright-statement>© White et al 2008</copyright-statement>
<copyright-year>2008</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/" xlink:type="simple">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:role="full-text" xlink:href="sextrans-84-ii12.pdf"></self-uri>
<abstract>
<sec>
<title>Background:</title>
<p>Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown.</p>
</sec>
<sec>
<title>Methods:</title>
<p>The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model
<italic>STDSIM</italic>
fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness.</p>
</sec>
<sec>
<title>Results:</title>
<p>Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (<5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA">
<title>Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa</title>
</titleInfo>
<name type="personal">
<namePart type="given">R G</namePart>
<namePart type="family">White</namePart>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">E E</namePart>
<namePart type="family">Freeman</namePart>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">K K</namePart>
<namePart type="family">Orroth</namePart>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">R</namePart>
<namePart type="family">Bakker</namePart>
<affiliation>Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">H A</namePart>
<namePart type="family">Weiss</namePart>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">N</namePart>
<namePart type="family">O’Farrell</namePart>
<affiliation>Pasteur Suite, Ealing Hospital, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">A</namePart>
<namePart type="family">Buvé</namePart>
<affiliation>Institute of Tropical Medicine, Antwerp, Belgium</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">R J</namePart>
<namePart type="family">Hayes</namePart>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">J R</namePart>
<namePart type="family">Glynn</namePart>
<affiliation>London School of Hygiene and Tropical Medicine, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo>
<publisher>BMJ Publishing Group Ltd</publisher>
<dateIssued encoding="w3cdtf">2008-10</dateIssued>
<dateCreated encoding="w3cdtf">2008-09-17</dateCreated>
<copyrightDate encoding="w3cdtf">2008</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<abstract>Background: Herpes simplex virus type 2 (HSV-2) infection increases acquisition and transmission of HIV, but the results of trials measuring the impact of HSV-2 therapy on HIV genital shedding and HIV acquisition are mixed, and the potential impact of HSV-2 therapy on the incidence of HIV at the population level is unknown. Methods: The effects of episodic and suppressive HSV-2 therapy were simulated using the individual-level model STDSIM fitted to data from Cotonou, Benin (relatively low HIV prevalence) and Kisumu, Kenya (high HIV prevalence). Clinician- and patient-initiated episodic therapy, started when symptomatic, were assumed to reduce ulcer duration. Suppressive therapy, given regardless of symptoms, was also assumed to reduce ulcer frequency and HSV-2 infectiousness. Results: Clinician-initiated episodic therapy in the general population had almost no effect on the incidence of HIV. The impact of patient-initiated therapy was higher because of earlier treatment initiation, but still low (<5%) unless symptom recognition and treatment-seeking behaviour were very high. Suppressive therapy given to female sex workers (FSW) in Kisumu had little effect on population HIV incidence. In Cotonou, suppressive therapy in FSW with high coverage and long duration reduced population HIV incidence by >20% in the long term. Impact was increased in both cities by also treating a proportion of their clients. Long-term suppressive therapy with high coverage in the general population could reduce HIV incidence by more than 30%. Conclusions: These results show that HSV-2 therapy could potentially have a population-level impact on the incidence of HIV, especially in more concentrated epidemics. However, a substantial impact requires high coverage and long duration therapy, or very high symptom recognition and treatment-seeking behaviour.</abstract>
<relatedItem type="host">
<titleInfo>
<title>Sexually Transmitted Infections</title>
</titleInfo>
<titleInfo type="abbreviated">
<title>Sex Transm Infect</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">1368-4973</identifier>
<identifier type="eISSN">1472-3263</identifier>
<identifier type="PublisherID">sti</identifier>
<identifier type="PublisherID-hwp">sextrans</identifier>
<identifier type="PublisherID-nlm-ta">Sex Transm Infect</identifier>
<part>
<date>2008</date>
<detail type="title">
<title>From efficacy to effectiveness; from effectiveness to impact</title>
</detail>
<detail type="volume">
<caption>vol.</caption>
<number>84</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>Suppl 2</number>
</detail>
<extent unit="pages">
<start>ii12</start>
</extent>
</part>
</relatedItem>
<identifier type="istex">0956EE2D6869A23BCC72701C677045799E4669CB</identifier>
<identifier type="ark">ark:/67375/NVC-5LC8PKZ3-L</identifier>
<identifier type="DOI">10.1136/sti.2008.029918</identifier>
<identifier type="href">sextrans-84-ii12.pdf</identifier>
<identifier type="ArticleID">st29918</identifier>
<identifier type="PMID">18799486</identifier>
<identifier type="local">sextrans;84/Suppl_2/ii12</identifier>
<accessCondition type="use and reproduction" contentType="open-access">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</accessCondition>
<recordInfo>
<recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource>
<recordOrigin>© White et al 2008</recordOrigin>
</recordInfo>
</mods>
<json:item>
<extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/metadata/json</uri>
</json:item>
</metadata>
<annexes>
<json:item>
<extension>jpeg</extension>
<original>true</original>
<mimetype>image/jpeg</mimetype>
<uri>https://api.istex.fr/document/0956EE2D6869A23BCC72701C677045799E4669CB/annexes/jpeg</uri>
</json:item>
</annexes>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000256 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000256 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:0956EE2D6869A23BCC72701C677045799E4669CB
   |texte=   Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa
}}

Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024